$136.64
-0.45-0.33%
At Close: -
$136.64
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Quest Diagnostics
DGXNYSE
Quest Diagnostics (NYSE:DGX) Stock, Analyst Ratings, Price Targets, Predictions
Quest Diagnostics Inc has a consensus price target of $150.4, established from looking at the 55 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, Barclays, and Citigroup on May 30, 2024, April 25, 2024, and April 24, 2024. With an average price target of $148 between JP Morgan, Barclays, and Citigroup, there's an implied 8.31% upside for Quest Diagnostics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Barclays
Citigroup
UBS
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Quest Diagnostics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/30/2024 | Buy Now | 13.44% | JP Morgan | Lisa Gill | $152 → $155 | Maintains | Neutral | Get Alert |
| 04/25/2024 | Buy Now | 5.39% | Barclays | Stephanie Davis | $138 → $144 | Maintains | Equal-Weight | Get Alert |
| 04/24/2024 | Buy Now | 6.12% | Citigroup | Patrick Donnelly | $135 → $145 | Maintains | Neutral | Get Alert |
| 04/24/2024 | Buy Now | 6.85% | UBS | Kevin Caliendo | $139 → $146 | Maintains | Neutral | Get Alert |
| 04/24/2024 | Buy Now | 9.78% | Truist Securities | David Macdonald | $145 → $150 | Maintains | Hold | Get Alert |
| 04/24/2024 | Buy Now | 13.44% | Mizuho | Ann Hynes | $150 → $155 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 6.12% | Truist Securities | David Macdonald | → $145 | Reiterates | Hold → Hold | Get Alert |
| 02/26/2024 | Buy Now | -1.2% | Leerink Partners | Michael Cherny | → $135 | Initiates | → Market Perform | Get Alert |
| 02/07/2024 | Buy Now | 13.44% | Jefferies | Brian Tanquilut | $140 → $155 | Upgrade | Hold → Buy | Get Alert |
| 02/02/2024 | Buy Now | 6.12% | Truist Securities | David Macdonald | $150 → $145 | Maintains | Hold | Get Alert |
| 12/20/2023 | Buy Now | 9.78% | Truist Securities | David Macdonald | $145 → $150 | Maintains | Hold | Get Alert |
| 12/12/2023 | Buy Now | 17.1% | B of A Securities | Derik De Bruin | $140 → $160 | Upgrade | Neutral → Buy | Get Alert |
| 12/11/2023 | Buy Now | 6.12% | Citigroup | Patrick Donnelly | $130 → $145 | Maintains | Neutral | Get Alert |
| 12/07/2023 | Buy Now | 0.26% | UBS | Kevin Caliendo | $135 → $137 | Maintains | Neutral | Get Alert |
| 11/17/2023 | Buy Now | 9.05% | JP Morgan | John Stansel | $148 → $149 | Maintains | Neutral | Get Alert |
| 11/06/2023 | Buy Now | 2.46% | Piper Sandler | David Westenberg | $130 → $140 | Maintains | Neutral | Get Alert |
| 10/25/2023 | Buy Now | -4.86% | Citigroup | Patrick Donnelly | $142 → $130 | Maintains | Neutral | Get Alert |
| 10/16/2023 | Buy Now | -4.86% | Piper Sandler | David Westenberg | $145 → $130 | Maintains | Neutral | Get Alert |
| 08/03/2023 | Buy Now | 6.12% | Morgan Stanley | Ricky Goldwasser | $145 → $145 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/29/2023 | Buy Now | 6.12% | Piper Sandler | David Westenberg | → $145 | Initiates | → Neutral | Get Alert |
| 05/10/2023 | Buy Now | 6.12% | Morgan Stanley | Ricky Goldwasser | $158 → $145 | Maintains | Equal-Weight | Get Alert |
| 05/02/2023 | Buy Now | 8.31% | B of A Securities | Derik De Bruin | $166 → $148 | Downgrade | Buy → Neutral | Get Alert |
| 04/03/2023 | Buy Now | 3.92% | Citigroup | Patrick Donnelly | $125 → $142 | Upgrade | Sell → Neutral | Get Alert |
| 03/17/2023 | Buy Now | 17.1% | Truist Securities | David Macdonald | $170 → $160 | Maintains | Hold | Get Alert |
| 03/17/2023 | Buy Now | 20.76% | Mizuho | Ann Hynes | → $165 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 2.46% | Wells Fargo | Timothy Daley | $135 → $140 | Maintains | Equal-Weight | Get Alert |
| 01/25/2023 | Buy Now | 6.85% | Credit Suisse | Jonathan Yong | $143 → $146 | Maintains | Neutral | Get Alert |
| 01/23/2023 | Buy Now | 16.36% | Evercore ISI Group | Elizabeth Anderson | → $159 | Initiates | → In-Line | Get Alert |
| 01/12/2023 | Buy Now | 12.7% | Baird | Eric Coldwell | $143 → $154 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 15.63% | Morgan Stanley | Ricky Goldwasser | $146 → $158 | Maintains | Equal-Weight | Get Alert |
| 12/14/2022 | Buy Now | 20.76% | Mizuho | Ann Hynes | $160 → $165 | Maintains | Buy | Get Alert |
| 11/17/2022 | Buy Now | -8.52% | Citigroup | Patrick Donnelly | $145 → $125 | Downgrade | Neutral → Sell | Get Alert |
| 10/21/2022 | Buy Now | 6.85% | Morgan Stanley | Ricky Goldwasser | $142 → $146 | Maintains | Equal-Weight | Get Alert |
| 10/21/2022 | Buy Now | 2.46% | Deutsche Bank | Pito Chickering | $129 → $140 | Maintains | Hold | Get Alert |
| 08/22/2022 | Buy Now | 3.92% | Morgan Stanley | Erin Wright | → $142 | Assumes | → Equal-Weight | Get Alert |
| 07/22/2022 | Buy Now | 17.1% | Mizuho | Ann Hynes | $185 → $160 | Maintains | Buy | Get Alert |
| 07/22/2022 | Buy Now | 4.65% | Credit Suisse | A.J. Rice | $158 → $143 | Maintains | Neutral | Get Alert |
| 05/03/2022 | Buy Now | 3.92% | Morgan Stanley | Ricky Goldwasser | $145 → $142 | Maintains | Equal-Weight | Get Alert |
| 04/25/2022 | Buy Now | 9.78% | Wells Fargo | Timothy Daley | $145 → $150 | Maintains | Equal-Weight | Get Alert |
| 04/22/2022 | Buy Now | 19.29% | B of A Securities | Derik De Bruin | $166 → $163 | Maintains | Buy | Get Alert |
| 04/04/2022 | Buy Now | — | Citigroup | Patrick Donnelly | — | Downgrade | Buy → Neutral | Get Alert |
| 02/23/2022 | Buy Now | 1.73% | UBS | Kevin Caliendo | $160 → $139 | Downgrade | Buy → Neutral | Get Alert |
| 02/14/2022 | Buy Now | 6.12% | Morgan Stanley | Ricky Goldwasser | $159 → $145 | Maintains | Equal-Weight | Get Alert |
| 02/04/2022 | Buy Now | 6.12% | Wells Fargo | Dan Leonard | $160 → $145 | Maintains | Equal-Weight | Get Alert |
| 02/02/2022 | Buy Now | -1.2% | Jefferies | Brian Tanquilut | → $135 | Downgrade | Buy → Hold | Get Alert |
| 01/28/2022 | Buy Now | -5.59% | Deutsche Bank | Pito Chickering | → $129 | Downgrade | Buy → Hold | Get Alert |
| 01/05/2022 | Buy Now | 24.41% | Truist Securities | David Macdonald | $150 → $170 | Maintains | Hold | Get Alert |
| 12/17/2021 | Buy Now | 16.36% | Morgan Stanley | — | — | Maintains | Equal-Weight | Get Alert |
| 12/14/2021 | Buy Now | 17.1% | Wells Fargo | Dan Leonard | — | Maintains | Equal-Weight | Get Alert |
| 12/13/2021 | Buy Now | 24.41% | Keybanc | — | — | Maintains | Overweight | Get Alert |
| 10/26/2021 | Buy Now | 9.78% | Wells Fargo | Dan Leonard | — | Maintains | Equal-Weight | Get Alert |
| 09/01/2021 | Buy Now | 22.95% | Keybanc | Donald Hooker | — | Maintains | Overweight | Get Alert |
| 08/31/2021 | Buy Now | 20.76% | Morgan Stanley | Craig Hettenbach | — | Maintains | Equal-Weight | Get Alert |
| 08/19/2021 | Buy Now | 21.49% | Mizuho | Ann Hynes | — | Maintains | Buy | Get Alert |
| 08/13/2021 | Buy Now | 9.78% | Credit Suisse | — | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Quest Diagnostics (DGX) stock?
The latest price target for Quest Diagnostics (NYSE:DGX) was reported by JP Morgan on May 30, 2024. The analyst firm set a price target for $155.00 expecting DGX to rise to within 12 months (a possible 13.44% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Quest Diagnostics (DGX)?
The latest analyst rating for Quest Diagnostics (NYSE:DGX) was provided by JP Morgan, and Quest Diagnostics maintained their neutral rating.
When was the last upgrade for Quest Diagnostics (DGX)?
The last upgrade for Quest Diagnostics Inc happened on February 7, 2024 when Jefferies raised their price target to $155. Jefferies previously had a hold for Quest Diagnostics Inc.
When was the last downgrade for Quest Diagnostics (DGX)?
The last downgrade for Quest Diagnostics Inc happened on May 2, 2023 when B of A Securities changed their price target from $166 to $148 for Quest Diagnostics Inc.
When is the next analyst rating going to be posted or updated for Quest Diagnostics (DGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quest Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quest Diagnostics was filed on May 30, 2024 so you should expect the next rating to be made available sometime around May 30, 2025.
Is the Analyst Rating Quest Diagnostics (DGX) correct?
While ratings are subjective and will change, the latest Quest Diagnostics (DGX) rating was a maintained with a price target of $152.00 to $155.00. The current price Quest Diagnostics (DGX) is trading at is $136.64, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.